ZEALAND PHARMA A/S (22Z.DE) Stock Earnings & Estimates
Europe - FRA:22Z - DK0060257814 - Common Stock
60.34 EUR
+60.34 (+Infinity%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 103.986M -4.20% | 342.788M 229.65% | 62.691M -81.71% | 9.562B 15,152.59% | 4.889B -48.87% | 3.545B -27.49% | 1.869B -47.28% | 3.192B 70.79% | 2.987B -6.42% | 5.277B 76.67% | 8.14B 54.25% | |
| EBITDA YoY % growth | -657.9M 11.32% | -536.152M 18.51% | -1.243B -131.88% | 565.59M 145.49% | -43.413M -107.68% | 183.92M 523.65% | 6.825M -96.29% | 771.86M 11,209.30% | -338.321M -143.83% | N/A | N/A | |
| EBIT YoY % growth | -775.861M 0.80% | -561.238M 27.66% | -1.269B -126.12% | 6.48B 610.61% | 1.423B -78.04% | -801.496M -156.32% | -2.713B -238.43% | -1.844B 32.02% | -766.456M 58.43% | 802.58M 204.71% | 3.048B 279.78% | |
| Operating Margin | -746.12% | -163.73% | -2,024.33% | 67.77% | 29.11% | -22.61% | -145.13% | -57.77% | -25.66% | 15.21% | 37.44% | |
| EPS YoY % growth | -26.02 -9.56% | -12.44 52.19% | -16.27 -30.79% | 91.04 659.55% | 20.36 -77.63% | -7.54 -137.01% | -32.23 -327.66% | -22.79 29.30% | -0.85 96.27% | 14.72 1,829.73% | 33.63 128.49% |
All data in DKK
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -8.04 -113.27% | -6.96 -68.94% | -9.26 -94.93% | 0.14 -99.87% | -4.14 48.46% | 17.96 358.07% |
| Revenue Q2Q % growth | 19.8M 348.47% | 156.78M 1,631.23% | 9.027M 11.55% | 838.64M -90.77% | 10.608M -46.42% | 4.051B 2,483.88% |
| EBITDA Q2Q % growth | -590.702M -79.09% | -500.116M -33.93% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -651.228M -86.38% | -589.479M -47.64% | -783.666M -103.31% | -49.368M -100.58% | -984.759M -51.22% | 2.935B 597.90% |
All data in DKK
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 107.61 2,404.28% | 113.92 | -6.31 | -5.54% |
| Q1 2025 Q2Q % growth | -4.75 -28.03% | -0.66 | -4.09 | -623.12% |
| Q4 2024 Q2Q % growth | -4.12 6.58% | -5.37 | 1.25 | 23.23% |
| Q3 2024 Q2Q % growth | -3.77 -406.50% | -3.63 | -0.14 | -4.00% |
| Q2 2024 Q2Q % growth | -4.67 15.09% | -4.09 | -0.58 | -14.25% |
| Q1 2024 Q2Q % growth | -3.71 1.33% | -4.28 | 0.57 | 13.40% |
| Q4 2023 Q2Q % growth | -4.41 33.28% | -3.93 | -0.48 | -12.15% |
| Q3 2023 Q2Q % growth | 1.23 138.32% | -2.37 | 3.60 | 151.87% |
| Q2 2023 Q2Q % growth | -5.50 50.18% | -4.79 | -0.71 | -14.85% |
| Q1 2023 Q2Q % growth | -3.76 27.13% | -3.80 | 0.04 | 1.17% |
| Q4 2022 Q2Q % growth | -6.61 -1.85% | -5.87 | -0.74 | -12.60% |
| Q3 2022 Q2Q % growth | -3.21 30.37% | -5.30 | 2.09 | 39.48% |
| Q2 2022 Q2Q % growth | -11.04 -60.70% | -7.71 | -3.33 | -43.17% |
| Q1 2022 Q2Q % growth | -5.16 10.73% | -6.75 | 1.59 | 23.58% |
| Q4 2021 Q2Q % growth | -6.49 33.50% | -6.48 | -0.01 | -0.20% |
| Q3 2021 Q2Q % growth | -4.61 19.97% | -6.28 | 1.67 | 26.59% |
| Q2 2021 Q2Q % growth | -6.87 -337.58% | -6.28 | -0.59 | -9.47% |
| Q1 2021 Q2Q % growth | -5.78 -16.06% | -6.29 | 0.51 | 8.16% |
| Q4 2020 Q2Q % growth | -9.76 -94.81% | -5.57 | -4.19 | -75.33% |
| Q3 2020 Q2Q % growth | -5.76 -67.44% | -5.38 | -0.38 | -7.10% |
| Q2 2020 Q2Q % growth | -1.57 63.74% | -0.86 | -0.71 | -82.52% |
| Q1 2020 Q2Q % growth | -4.98 -20.58% | -4.99 | 0.01 | 0.22% |
| Q4 2019 Q2Q % growth | -5.01 | -1.07 | -3.94 | -367.79% |
| Q3 2019 Q2Q % growth | -3.44 | -2.34 | -1.10 | -47.27% |
| Q2 2019 Q2Q % growth | -4.33 | -2.72 | -1.61 | -59.29% |
| Q1 2019 Q2Q % growth | -4.13 | -4.18 | 0.05 | 1.16% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 9.088B 26,527.65% | 9.421B | -332.716M | -3.53% |
| Q1 2025 Q2Q % growth | 8.092M -46.37% | 31.865M | -23.773M | -74.61% |
| Q4 2024 Q2Q % growth | 9.056M -61.02% | 24.864M | -15.808M | -63.58% |
| Q3 2024 Q2Q % growth | 4.415M -98.51% | 55.866M | -51.451M | -92.10% |
| Q2 2024 Q2Q % growth | 34.131M 227.96% | 13.043M | 21.088M | 161.68% |
| Q1 2024 Q2Q % growth | 15.089M 10.72% | 9.301M | 5.788M | 62.23% |
| Q4 2023 Q2Q % growth | 23.235M -2.88% | 10.113M | 13.122M | 129.75% |
| Q3 2023 Q2Q % growth | 295.517M 576.02% | 59.088M | 236.429M | 400.13% |
| Q2 2023 Q2Q % growth | 10.407M -71.37% | 12.508M | -2.101M | -16.80% |
| Q1 2023 Q2Q % growth | 13.628M -9.61% | 7.217M | 6.411M | 88.83% |
| Q4 2022 Q2Q % growth | 23.925M 78.12% | 14.534M | 9.391M | 64.61% |
| Q3 2022 Q2Q % growth | 43.714M -19.33% | 43.86M | -146K | -0.33% |
| Q2 2022 Q2Q % growth | 36.347M -0.55% | 54.444M | -18.097M | -33.24% |
| Q1 2022 Q2Q % growth | 15.077M 164.32% | 64.928M | -49.851M | -76.78% |
| Q4 2021 Q2Q % growth | 13.432M -78.80% | 82.777M | -69.345M | -83.77% |
| Q3 2021 Q2Q % growth | 54.188M -4.14% | 71.741M | -17.553M | -24.47% |
| Q2 2021 Q2Q % growth | 36.547M -83.46% | 63.757M | -27.21M | -42.68% |
| Q1 2021 Q2Q % growth | 5.704M -54.06% | 63.276M | -57.572M | -90.99% |
| Q4 2020 Q2Q % growth | 63.356M 451.26% | 108.01M | -44.654M | -41.34% |
| Q3 2020 Q2Q % growth | 56.526M 469.70% | 78.799M | -22.273M | -28.27% |
| Q2 2020 Q2Q % growth | 221.016M 1,009.63% | 204.99M | 16.026M | 7.82% |
| Q1 2020 Q2Q % growth | 12.416M | 16.32M | -3.904M | -23.92% |
| Q4 2019 Q2Q % growth | 11.493M | 159.38M | -147.887M | -92.79% |
| Q3 2019 Q2Q % growth | 9.922M | 32.012M | -22.09M | -69.01% |
| Q2 2019 Q2Q % growth | 19.918M | 12.75M | 7.168M | 56.22% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A |
| Revenue | N/A | N/A | N/A | N/A |